Update on neoadjuvant treatment of breast cancer
|
|
- Arnold Stevens
- 8 years ago
- Views:
Transcription
1 Update on neoadjuvant treatment of breast cancer
2 «IS PATHOLOGIC COMPLETE RESPONSE STILL A GOOD SURROGATE OF SURVIVAL?»
3 Complete histological response varies according to tumoral type pcr (%) Luminal A (N=572) Luminal B (HER2-) (N=211) Luminal B (HER2+) (N=281) HER2+ (non-luminal) (N=178) Triple-negative N=362) Untch M, et al J Clin Oncol. 2010, Apr 20;28(12):
4 Prognostic impact of pathologic complete response (pcr) on disease-free survival (DFS) in 4,193 patients according to breast cancer intrinsic subtype. with luminal A luminal B, HER2 neg luminal B, HER2 pos pcr rate after neoadjuvant chemotherapy is associated with better outcome only for patients with: HER2-positive/hormone receptor negative or triple-negative and some more aggressive HER2-negative/hormone HER2-positive (nonluminal luminal B, HER2 neg receptor positive tumours. TN von Minckwitz G et al. JCO 2012;30:
5 Update HER2+++ breast cancers What s new?
6 Unresolved questions Noah study (and other phase II studies) have shown that Traztuzumab should be added to chemotherapy in neoadjuvant setting Questions : Traztuzumab and Anthracyclins combination? Precocity of Traztuzumab use?
7 Trastuzumab and anthracyclin Joint use of anthracyclin and Trastuzumab in neoadjuvant studies in HER2+++ patients, acceptable toxicity This combination is doubtfull as for its innocuousness Retrospective analysis of 583 patients who received anthracyclins and Traztuzumab (3 neoadjuvant trials) Cardiac toxicity rate (linear variable ) Increase cardiac toxicity (OR = 1,95, 95% CI 1,16-3,29) 44 cardiac events in the group with T vs 28 in the group without T Bozovic-Spasojevic ILancet Oncol Mar;12(3):209-11
8 What is the optimal time for Traztuzumab initiation? There are no direct data answering to this question as there are no studies comparing Traztuzumab in neoadjuvant vs adjuvant setting (except Remagus study.) In metastatic setting, arguments in favor of an early use (1) In adjuvant setting (NCCTG) in favor of an early use With a 6 years follow up DFS (2) AC-P (12 weeks) = 71,9 % AC-P (12 weeks then )-T = 80,1 % AC-PT (concommitant) = 84,2 % HR : 0,69 [0,57-0,85], p = 0,0005 HR : 0,75 [0,60-1,11], p = 0,02 (1) Marty et al, J clin oncol, 2005, (23) (2) Perez EA J Clin Oncol. 2011, 29(34):
9 The interest of double blockage?
10 Lapatinib in neoadjuvant Tyrosine Kinase inhibitor of EGFR and HER2 Efficacy in metastatic breast cancers HER2 +++ combined with capecitabine or to Traztuzumab Geyer CE N Engl J Med Apr 5;356(14):1487. Blackwell KL, et al: J Clin Oncol Jul 20;30(21):
11 HER2 signaling pathway Trastuzumab HER2/HER3 PTEN TORC2 Lapatinib PI3K PIP 3 Akt PDK1 Ras Raf MEK Anti HER2 treatment are monoclonal antibodies against extracellular portion (traztuzumab) and small molecules which inhibit tyrosin kinase (lapatinib). Tuberin Erk Rheb TORC1 Rsk Baselga J et al. SABCS 2010
12 Two randomised trials
13 Neo-ALTTO Breast cancer HER2+, T > 2 cm (no inflammatory ) FEVG > 50 % n = 450 Stratification : S 5 cm vs. S > 5 cm RE ou RP + vs. RE & RP n 0-1 vs. n 2 Surgery or not Conservative or no R A N D O M I S A T IO N lapatinib trastuzumab paclitaxel lapatinib trastuzumab paclitaxel 6 sem paclitaxel + 12 week s u r g e r y lapatinib trastuzumab lapatinib trastuzumab 34 week 52 semaines de traitement anti-her2 Baselga J et al. Lancet Feb 18;379(9816): F E C X 3
14 Neo-ALTTO Efficacy pcr et tpcr p = p = p = 0.34 p = % 29.5 % 51.3 % 20.0 % 27.6 % 46.9 % L T L + T n = 154 n = 149 n = 152 pcr L T L + T n = 150* n = 145* n = 145* tpcr Loco regional pcr L : lapatinib; T : trastuzumab; L+T : lapatinib plus trastuzumab pcr : pathologic complete response Baselga J et al. Lancet Feb 18;379(9816):
15 Neo-ALTTO Efficacy % of conservative surgery and % N- p = 0.14 p = 0.03 p > 0.5 p > % 38.9 % 41.4 % 48.0 % 56.6 % 69.0 % L T L + T n = 154 n = 149 n = 152 Conservative surgery L T L + T n = 150* n = 143* n = 147* Negative lymph nodes status L : lapatinib; T : trastuzumab; L+T : lapatinib plus trastuzumab Baselga J et al. Lancet Feb 18;379(9816):
16 GeparQuinto-HER2+ EC Doc Trastuzumab (T) T 6 months R EC Doc* 620 Pts 309 ECTH, 311 ECTL Lapatinib (L) T 12 months C : Cyclophosphamide 600 mg/m² E : Epirubicine 90 mg/m² T : Trastuzumab 6 (8) mg/kg * + G-CSF Doc : Docetaxel 100 mg/m² L : mg/j p.o. (cycles de 3 semaines) Untch M et al. Lancet Oncol Feb;13(2):135-44
17 GeparQuinto pcr (non invasive / no invasive carcinoma in breast and lymph nodes by central review ) 50,0% 45,0% 40,0% 35,0% 30,0% 25,0% 20,0% 15,0% 10,0% 5,0% 0,0% EC-Doc + T p < 0.03 EC-Doc + L Untch M et al. Lancet Oncol Feb;13(2):135-44
18 GeparQuinto pcr according to subgroups (pre dfined and stratified 50% 45% 40% Negative RE/RP Positive RE/RP T1-3 and N0-2 T4 or N3 35% 30% 25% 20% 15% 10% 5% 39 % 28 % 26 % 16 % 31 % 20 % 31 % 30 % 0% EC-Doc + H EC-Doc + L EC-Doc + H EC-Doc + L EC-Doc + H EC-Doc + L EC-Doc + H EC-Doc + L Untch M et al. Lancet Oncol Feb;13(2):135-44
19 NSABP B-41 : lapatinib evaluation in neoadjuvant treatment in HER2 +++ breast cancer (1) Operable HER breast cancer 529 ptes R AC - wp + T AC -wp + L Trastuzumab for one year AC- wp + T + L T = trastuzumab ; L = lapatinib ; wp = paclitaxel hebdomadaire Criteria : pcr, cardiac events, progresssion free survival, overall survival ASCO D après Robidoux A et al., LBA506 actualisé
20 NSABP B-41 : lapatinib evaluation in neoadjuvant treatment in HER2 +++ breast cancer (2) Pricipal criteria pcr rate in the breast (non statistically significant ) Secondary criteria pcr rate in the breast and lymph nodes : limit for significativity Taux de réponse histologique p = 0,056 p = 0,78 49,4 47,4 60, AC wp + T (n = 176) wp = paclitaxel hebdomadaire AC wp + L (n = 171) AC wp + T + L (n = 117) ASCO D après Robidoux A et al., LBA506 actualisé
21 Pertuzumab :inhibits HER2 dimerisation Monoclonal anti body against a different target of HER2- HER3 Pertuzumab is a humanised monoclonal antibody, first of a new class : HER2 dimerisation inhibitor With the inhibition of HER2 dimerisation, pertuzumab inhibits HER 2 signaling patways spark off proliferation and survival of cellular cells. Pertuzumab prevent HER2-3 formation Franklin et al. Cancer Cell 2004;5: Augus et al. Cancer Cell 2002;2:
22 surgery NeoSphere Design of the study TH (n = 107) docetaxel + trastuzumab FEC /3 w x 3 trastuzumab /3 w cycles 5 17 HER2 +++ breast cancers operable > 2cm or locally advanced or inflammatory (n = 417) THP (n = 107) docetaxel + trastuzumab + pertuzumab HP (n = 107) trastuzumab + pertuzumab FEC /3 w x 3 trastuzumab /3 w cycles 5 17 docetaxel /3 w x 4 FEC /3 w x 3 trastuzumab /3 w cycles 5 17 TP (n = 96) docetaxel + pertuzumab Schéma : /3 weeks x 4 FEC /3 w x 3 trastuzumab /3 sem cycles 5 21 CS, cancer du sein; FEC, 5-fluorouracile, épirubicine et cyclophosphamide *Localement avancé = T2 3, N2 3, M0 ou T4a c, tout N, M0; opérable = T2 3, N0 1, M0; inflammatoire = T4d, tout N, M0 H, trastuzumab; P, pertuzumab; T, docetaxel Gianni L, Lancet Oncol Jan;13(1):25-32.
23 NeoSphere pcr (ITT) p = p = p = TH THP HP TP H, trastuzumab; P, pertuzumab; T, docetaxel Gianni L et al. SABCS 2010
24 Conclusion These data show that combining anti her2 +++ therapies and transduction pathways inhibitors could bypass resistance mecanisms and improve patients outcome without too much toxicity but a cost..
25 Biomarkers which predict who benefit to the addition of pertuzumab to Traztuzumab In the cleopatra study there are no blood predictive markers nor tissue markers J. Baselga et al., SABCS 2012, S5-1
26 Bevacizumab in neoadjuvant treatment for breast cancer Interest in triple negative cancers?
27 Biology of triple negative breast cancers identification of potential targets Triple negative breast cancers come from myoepithelial cells CK5-6, EGFR (1) Kinase Dysregulation Loss of PTEN (2) Activation of Akt pathway Amplification of FGF2, VEGFA, AR TN breast cancer high level of intracellular VEGF TN could have a higher sensitivity, to angiogenic inhibitors 1) Jones et al, ) Andre ) Turner et al, ) Linderholm et al, Ann Oncol, 20, 2009,
28 Bevacizumab added to neoadjuvant chemotherapy for breast cancer Harry D Bear;M.D; Ph D New england journal of médicine ; Janvier 2012
29 Design of the study Biopsy for biomarkers EC EC EC EC Operable breast cancers T2 T3 HER2 neg N: 1206 ( ) R EC EC EC EC SURGERY EC EC EC EC E: Epirubicine 60 mg/m toutes les 3 semaines C: Cyclophosphamide: 600 mg/m toutes les 3 semaines X: Capecitabine 825 mg/m2 de J1 à J14 GEM:Gencitabine 1000 mg/m2 J1J8 BEV: Bevacizumab 15mg/m2 T: Docetaxel 100 mg/m2 dans le groupe 1 et 75mg/m2 groupe 2 et 3
30 Bevacizumab: pcr rate in the breast p = 0,75 p = 0, ,7 % T-AC p = 0,009 36,1 % 35,8% 31,6 % 27,6% 23,5 % TG-AC TX-AC T-AC TG-AC TX-AC Without Bevacizumab With bevacizumab
31 Bevacizumab: pcr rate in the breast and lymph nodes Bevacizumab addition do not significatively increase pcr rate in breast and lymph nodes (P=0,08)
32 Bevacizumab: pcr rate in breast and lymph nodes
33 pcr, % + IC 95 % Bevacizumab: pcr rate in the breast and lymph nodes in patients with RH+ tumors ,1 % p = 0,03 16,8% Bevacizumab addition statistically increase pcr rate in breast and lymph nodes in RH+ tumors (p=0,03) 0 Without Bevacizumab With Bevacizumab
34
35 Design of the study, 1948 patients No response (clinical and/or ultrasound) >switch Taxol hebdo + Everolimus (group 2) pcr Her 2 (group 1) EC EC+ Bev Réponse R T T+ Bev 14,9 % 18,4 % P = 0,04 E: Epirubicine 90 mg/m2 C: Cyclophosphamide: 600 mg/m2 T:Docetaxel 100mg/m2 BEV: Bevacizumab 15mg/kg T: Docetaxel 100 mg/m2
36 Sub groups analysis Interaction test negative NS (p = 0.07) pcr in TN (663 pts) : 39,3% vs 27,9%, p = 0,0033 pcr in RH + 7,8% vs 7,8%, (p=1,00)
37 Comparison of the two studies pcr increase in the entire population low. pcr increase in TN tumors not found in NSABP study. BUT Smaller population (490 ptes) Inflammatory and T4 tumors in the Geparquinto not in the NSABP trial Anthracyclins given before in the Geparquinto Docetaxel dosage superior in the Geparquinto during 2 cycles Beva given for 2 cycles with antracyclins Only patients with objective response in the gepar received the Beva
38 Translational studies could targeted the patients who will answer «maybe» to Bevazusimab
39 Conclusion The neoadjuvant setting gives the unique opportunity to get insights in breast cancer biology It allows: to evaluate new therapies to find predictive factors for better individualization of the treatment.
Miquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationNew Approval Mechanism for Breast Cancer using pathologic Complete Response
New Approval Mechanism for Breast Cancer using pathologic Complete Response Sandra M. Swain, MD, FACP Medical Director, Washington Cancer Institute MedStar Washington Hospital Center Professor of Medicine
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationBreast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania
Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationThe current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment
The current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment Ahmad Awada, MD, PhD Head of Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles
More informationBreast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationAdjuvant Therapy with Trastuzumab
Adjuvant Therapy with Trastuzumab Hiroji Iwata, M.D. Department of Breast Oncology, Aichi Cancer Center Hospital Although this presentation includes information regarding pharmaceuticals (including products
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationSeconda linea di trattamento
XVIII Congresso Nazionale CIPOMO Roma, Giugno 2013 Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Seconda linea di trattamento Giorgio
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationHOW FAR WE VE COME: TREATING HER2- POSITIVE BREAST CANCER WITH TARGETED THERAPIES
HOW FAR WE VE COME: TREATING HER2- POSITIVE BREAST CANCER WITH TARGETED THERAPIES Javier Cortes, Vall d Hebron Institute of Oncology (VHIO), Medica Scientia Innovation Research (MedSIR) Barcelona, Spain
More informationQu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles
Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles FOM Lille 2013 1 Her2 breast cancer expression = Poor
More informationAdvances in Neoadjuvant and Adjuvant Therapy
Advances in Neoadjuvant and Adjuvant Therapy Kathy S. Albain, MD, FACP Director, Breast Clinical Research Program Co-Director, Breast Oncology Center Director of the Thoracic Oncology Program Professor
More informationBreast Cancer: Background
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of August 2014. All materials contained herein reflect the views of the faculty, and not those
More informationSan Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 10 14, 2013
Final Analysis of a Phase II, 3-Arm, Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by 6 cycles of Docetaxel and Carboplatin with Trastuzumab
More informationPositività per HER-2 nei carcinomi subcentimetrici
Positività per HER-2 nei carcinomi Antonella Ferro U.O. Oncologia Medica Trento Small Tumors Small tumors are becoming increasingly common with the use of mammography > screening Some of these tumors,
More informationBiomarker Trends in Breast Cancer Research
WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationtrastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd
trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd 06 December 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationPI3K signaling pathway a new target for breast cancer treatment
PI3K signaling pathway a new target for breast cancer treatment Introduction At the 37 th annual San Antonio Breast Cancer Symposium, SABCS, a number of interesting research trends, novelties as well as
More informationAdjuvant treatment of breast cancer patients with trastuzumab
doi:10.2478/v10019-007-0020-y review Adjuvant treatment of breast cancer patients with trastuzumab Erika Matos, Tanja Čufer Institute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, Slovenia
More informationInflammatory Breast Cancer: A Unique Pathologic Entity?
Inflammatory Breast Cancer: A Unique Pathologic Entity? Sandra M. Swain, M.D. Director, Washington Cancer Institute Washington Hospital Center Washington DC Outline Overview Therapy High dose chemotherapy
More informationESMO 2014 Summary Breast Cancer
ESMO 2014 Summary Breast Cancer 1 7. 1 0. 2 0 1 4 A N NA D U R I G OVA M E D I C A L O N CO LO GY U N I V E R S I T Y H O S P I TA L S O F G E N E VA Outline 1. Early Breast Cancer Her2+ Neoadjuvant: Lapatax
More informationHER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
More informationSAMO FoROMe Post-ESMO 2013 Breast Cancer
SAMO FoROMe Post-ESMO 2013 Breast Cancer Dr. med. Manuela Rabaglio Klinik und Poliklinik für Medizinische Onkologie Breast Cancer Track 300 Abstracts 142 Poster 11 Proffered paper 4 late breaking news
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationAppendix One. HER2-positive early breast cancer, its treatment and prognosis
Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationEsin Oktay, Özlem Yersal, Nezih Meydan, Mehmet SaLJroLlu, Ömer UyanJk, andsabribarutca. 1. Introduction. 2. Case Presentation
Case Reports in Oncological Medicine Volume 2013, Article ID 234391, 4 pages http://dx.doi.org/10.1155/2013/234391 Case Report Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast
More informationI. THE IMPORTANCE OF HER2 IN BREAST CANCER
I. THE IMPORTANCE OF HER2 IN BREAST CANCER The human epidermal growth factor receptors (HER), also known as ERBB receptors, are a family of signal transduction proteins. There are 4 family members in humans
More informationLOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT
LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationJennifer Diamond M.D. Assistant Professor Developmental Therapeutics and Breast Oncology University of Colorado Anschutz Medical Campus SUMO Fall
Jennifer Diamond M.D. Assistant Professor Developmental Therapeutics and Breast Oncology University of Colorado Anschutz Medical Campus SUMO Fall Meeting September 26, 2015 To understand the biology and
More informationThe Impact of Taxotere on Adjuvant Breast Cancer
The Impact of Taxotere on Adjuvant Breast Cancer a report by Pierre Fumoleau and Henri Roché Centre Georges François Leclerc, Dijon, and Institut Claudius Regaud, Toulouse, France DOI: 10.17925/EOH.2005.0.0.1l
More informationNeoadjuvant (Primary) Systemic Therapy
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO e. V. in der DGGG e.v. sowie in der DKG e.v. Guidelines Breast Version 2015.1 Neoadjuvant (Primary) Systemic Therapy Neoadjuvant
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationHER2-Positive Breast Cancer: Update on New and Emerging Agents
HER2-Positive Breast Cancer: Update on New and Emerging Agents Alexandra Drakaki, MD, and Sara A. Hurvitz, MD Abstract The most common malignancy and second leading cause of cancer-related death in women
More informationCurrent and future anti-her2 therapy in breast cancer
J BUON 2013; 18(1): 4-16 ISSN: 1107-0625 www.bu-on.org/jbuon E-mail: jbuon@ath.forthnet.gr REVIEW ARTICLE Current and future anti-her2 therapy in breast cancer S. Vrbic 1,2, I. Pejcic 1,2, S. Filipovic
More informationLa Terapia Personalizzata in Oncologia
AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA La Terapia Personalizzata in Oncologia Roma, 25-26 Ottobre 2011 Stato dell arte e prospettive della Target Therapy nei tumori mammari PierFranco Conte Department
More informationPROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.
PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationTriple negative Breast Cancer Patient
Triple negative Breast Cancer Patient Alison L Jones November 2013 Mrs Trisha Negative Aged 52) Diagnosed November 2001 T2 N1 (2/11)M0 Left breast. No family history WLE/ANC then FEC/T + RT Relapsed 2013
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationLung Cancer Research: From Prevention to Cure!
Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology
More informationBREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine
Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine
More informationPrognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy
Original Study Prognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy Sota Asaga, Takayuki Kinoshita, Takashi Hojo, Junko Suzuki, Kenjiro Jimbo, Hitoshi
More informationNeoadjuvant (Primary) Systemic Therapy
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO e. V. in der DGGG e.v. sowie in der DKG e.v. Guidelines Breast Version 2016.1 Neoadjuvant (Primary) Systemic Therapy Neoadjuvant
More informationLa biologia molecolare «driver» delle scelte terapeutiche: k mammario HER2+
La biologia molecolare «driver» delle scelte terapeutiche: k mammario HER2+ Dr.ssa Lucia Del Mastro U.O. Sviluppo Terapie Innovative IRCCS AOU San Martino-IST Verona, 18 settembre 2015 Copyright 2014 -
More informationAIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY
AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY THE HERMARK BREAST CANCER ASSAY HERmark is based on our proprietary VeraTag technology that precisely quantifies HER2 proteins and protein complexes
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationProgress in Treating Advanced Triple Negative Breast Cancer
Progress in Treating Advanced Triple Negative Breast Cancer Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Triple Negative Breast Cancer by Subtype
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationBioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy
BioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy Soonmyung Paik 1 ; Gyungyub Gong 2 ; Yap Yoon Sim 3 ; Tae- You Kim
More informationIn treating triple negative breast cancer,
Treatment of triple negative breast cancer Triple negative breast cancers, as a subgroup, are associated with a poor prognosis. But different subtypes within triple negative disease are associated with
More informationSymposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive
More informationHER2-positive Metastatic Breast Cancer: New Agents on the Horizon
Hong Kong J Radiol. 2012;15(Suppl):S51-6 REVIEW ARTICLE HER2-positive Metastatic Breast Cancer: New Agents on the Horizon W Yeo Department of Clinical Oncology, The Chinese University of Hong Kong, Prince
More informationNeoadjuvant Breast Cancer Therapy and Drug Development
Neoadjuvant Breast Cancer Therapy and Drug Development Patricia Cortazar, MD, and Paul G. Kluetz, MD The authors are affiliated with the Office of Hematology and Oncology Products at the Center for Drug
More informationTreatment Paradigm in NSCLC Treatment
Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status
More informationNovel Targets in Breast Cancer. Vandana Abramson, MD May 1, 2010
Novel Targets in Breast Cancer Vandana Abramson, MD May 1, 2010 Disclosure Information I have no financial relationships to disclose relevant to the content of this presentation. Breast ca: many diseases
More informationREVIEWS. Treatment of HER2-positive breast cancer: current status and future perspectives
Treatment of HER2-positive breast cancer: current status and future perspectives Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi and Luca Gianni Abstract The advent
More informationA disease of populations of cells that live, divide, invade and spread without regard to normal limits
1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationGynäkologische Onkologie-Klinische Studien
Gynäkologische Onkologie-Klinische Studien Breast cancer A randomized, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer
More informationClinical Management Protocol Chemotherapy Breast Cancer. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: BREAST CANCER Patient information given at each stage following agreed information pathway
More informationWhat is breast cancer?
Breast Cancer What is breast cancer? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines BREAST CANCER: A GUIDE FOR
More informationMeasurement of HER2. Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center
Measurement of HER2 Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center Trastuzumab Metastatic Adjuvant Lapatinib Metastatic Trials Why Test
More informationOptimizing Anti-HER2 Therapy in Advanced Breast Cancer: Integrating New Data and Agents Into Practice
Optimizing Anti-HER2 Therapy in Advanced Breast Cancer: Integrating New Data and Agents Into Practice Learning Objectives Discuss recent clinical trials showing survival advantages in the treatment of
More informationMonoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.
Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationAbstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2
Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo
More informationCancer patients waiting for potentially live-saving treatments in UK
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
More informationBreast cancer: Diagnosis and complex treatment. Ibolya Czegle MD PhD Semmelweis University 3rd Department of Internal Medicine
Breast cancer: Diagnosis and complex treatment Ibolya Czegle MD PhD Semmelweis University 3rd Department of Internal Medicine Epidemiology Worldwide, breast cancer is the most frequently diagnosed life-threatening
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationNieuwe ontwikkelingen op het gebied van de angiogeneseremmers
Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers Emile Voest, MD, PhD Department of Medical Oncology University Medical Center Utrecht the Netherlands 4e Nascholing Targeted Therapy April
More informationClinical Progress in Antiangiogenic Therapy for Breast Cancer (BC)
TARGETING TUMOR ANGIOGENESIS Clinical Progress in Antiangiogenic Therapy for Breast Cancer (BC) Clinical Progress in Antiangiogenic Therapy for Breast Cancer (BC) Breast cancer, which comprises 29% of
More informationNancy E. Davidson, MD Johns Hopkins University. Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationLAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER
146 Experimental Oncology 37, 146 150, 2015 (June) Exp Oncol 2015 37, 2, 146 150 LAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER J. Zekri 1, 2, M. Mokhtar 3, S.M.
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationSequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study
JBUON 2013; 18(2): 314-320 ISSN: 1107-0625 www.jbuon.com E-mail: info@jbuon.com ORIGINAL ARTICLE Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationThe NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.
Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous
More informationWhat s New With HER2?
What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston
More information5.04.20. Perjeta. Perjeta (pertuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.20 Subject: Perjeta Page: 1 of 5 Last Review Date: June 19, 2015 Perjeta Description Perjeta (pertuzumab)
More informationAdvances in research will change the PROCEEDINGS THE FUTURE OF BREAST CANCER TREATMENT* Maura N. Dickler, MD ABSTRACT
THE FUTURE OF BREAST CANCER TREATMENT* Maura N. Dickler, MD ABSTRACT Advances in breast cancer research have led to the development of investigational agents that demonstrate efficacy against new targets,
More informationPrognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee
Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a
More informationREFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market
More informationManagement of Locally Advanced and Metastatic HER2-Positive Breast Cancer
Management of Locally Advanced and Metastatic HER2-Positive Breast Cancer Pretest Question #1 Which of the following is an antibody-drug conjugate indicated for use in HER2-positive metastatic breast cancer?
More informationCurriculum Vitae of Luca Gianni
Education: 1976: State University of Milan, Milan, Italy: Medical Doctor with honors 1981: State University of Milan, Milan, Italy: Board- Certified in Internal Medicine Brief Chronology of Activities
More informationTargeted Therapy in an Era of Genomic Medicine. George W. Sledge MD Stanford University
Targeted Therapy in an Era of Genomic Medicine George W. Sledge MD Stanford University Why Do Women Die of Breast Cancer? Bad biology Avoidable deaths Important subsets of breast cancers defined by molecular
More informationMetastatic Triple Negative Breast Cancer: Ongoing Trials. Joan Albanell Hospital del Mar, Barcelona
Metastatic Triple Negative Breast Cancer: Ongoing Trials Joan Albanell Hospital del Mar, Barcelona Metastatic Triple Negative Breast Cancer Spectrum Targeting Growth Factor Receptors Targeting Signaling
More information